Dyne Therapeutics, Inc. (DYN): Results of Operations and Financial Condition
Dyne Therapeutics, Inc. (DYN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 202
How this was made
The 30-second read
Why it matters
The FDA’s acceptance of the z-rostudirsen BLA and Priority Review with a defined PDUFA target date is a high-signal regulatory catalyst. The company also provides financing runway into Q2 2028, which can reduce dilution fears while it advances additional trials (HARMONIA, FORZETTO) and initiates DYNE-302 in FSHD.
Market read
Traders can update probability-weighted outcomes for z-rostudirsen based on the newly disclosed FDA review timeline, while monitoring burn rate and execution milestones into 2027.
What to watch
The 8-K also shows rising R&D and G&A costs and a large cash burn, so valuation may remain sensitive to burn rate and execution risk even with improved regulatory timing.
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Clinical and regulatory progress included Priority Review for z-rostudirsen and completion of enrollment in the ACHIEVE registrational expansion cohort, while operating spending and net loss were higher than the prior-year period.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expensesGAAP | $152.2 million | – | – |
| General and administrative expensesGAAP | $29.5 million | – | – |
| Net lossGAAP | $178.6 million | – | – |
| Net loss per basic and diluted shareGAAP | $1.08 per basic and diluted share | – | – |
| Cash, cash equivalents and marketable securitiesother | $898.5 million | – | – |
Q1 2027 outlook
- NoteDyne continues to expect a potential U.S. launch of z-rostudirsen in Q1 2027, assuming approval is received on the anticipated timeline.
- NotePDUFA target action date set for January 21, 2027.
- NoteTopline data from the ACHIEVE REC are planned for Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027.
- NoteDyne expects a potential U.S. launch of z-basivarsen in H1 2028, assuming the FDA grants Priority Review and approval is received on the anticipated timeline.
- NoteThe Company expects that its cash, cash equivalents and marketable securities as of June 30, 2026, together with the net proceeds from the July 2026 underwritten public offering, will be sufficient to fund its operations into the second quarter of 2028.
What drove it
- The increase in R&D expense was primarily due to increased manufacturing activity and higher clinical costs related to z-rostudirsen and z-basivarsen during the three months ended June 30, 2026.
- The increase in G&A expenses was primarily due to increased costs in preparation for the potential launch of z-rostudirsen.
- Dyne’s BLA was accepted for review by the FDA in July 2026, with Priority Review granted.
- Dyne completed enrollment of 71 participants in the registrational expansion cohort of ACHIEVE in June 2026.
- Dyne began dosing participants in the global confirmatory Phase 3 HARMONIA trial of z-basivarsen in July 2026.
- Dyne received clearance from the FDA in July 2026 for its IND application to initiate a Phase 1 clinical trial for DYNE-302 in FSHD.
Concerns
- Net loss for the three months ended June 30, 2026 was $178.6 million, compared with a net loss of $110.9 million for the three months ended June 30, 2025.
- R&D expenses were $152.2 million for the three months ended June 30, 2026 compared to $99.2 million for the three months ended June 30, 2025.
- G&A expenses were $29.5 million for the three months ended June 30, 2026 compared to $16.6 million for the three months ended June 30, 2025.
- Potential launch timelines for z-rostudirsen and z-basivarsen are conditional on regulatory approvals and anticipated timelines.
What to watch
- FDA action on the z-rostudirsen BLA by the PDUFA target action date of January 21, 2027.
- Potential U.S. launch of z-rostudirsen in Q1 2027, assuming approval is received on the anticipated timeline.
- Topline data from the ACHIEVE registrational expansion cohort planned for Q1 2027.
- Potential BLA submission for z-basivarsen in Q3 2027.
- Potential U.S. launch of z-basivarsen in H1 2028, assuming the FDA grants Priority Review and approval is received on the anticipated timeline.
- Execution of the global confirmatory Phase 3 FORZETTO and HARMONIA trials.
- Progression of DYNE-302 into its planned Phase 1 randomized, placebo-controlled, double-blind, MAD clinical trial in FSHD.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $898.5 million as of June 30, 2026.
- Dyne entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc. in June 2026, expanding its debt facility to up to $400 million.
- Dyne completed an underwritten public offering of 21,045,000 shares of its common stock at a public offering price of $20.50 per share in July 2026.
- The gross proceeds from the offering before deducting underwriting discounts and commissions and offering expenses payable by Dyne were approximately $431 million.
- The Company completed an underwritten public offering of 21,045,000 shares of its common stock for estimated net proceeds of approximately $405.0 million.
Analysis
Dyne reported a clinical-stage quarter centered on regulatory advancement and trial execution rather than commercial revenue. The FDA accepted the BLA for z-rostudirsen in exon 51 DMD, granted Priority Review and set a PDUFA target action date of January 21, 2027. The company also initiated the global confirmatory Phase 3 FORZETTO trial in May 2026 and continues to expect a potential U.S. launch of z-rostudirsen in Q1 2027, assuming approval is received on the anticipated timeline.
The DM1 program advanced through completion of enrollment of 71 participants in the ACHIEVE registrational expansion cohort in June 2026 and the start of dosing in the Phase 3 HARMONIA trial in July 2026. Dyne plans topline ACHIEVE REC data in Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027. The company expects a potential U.S. launch of z-basivarsen in H1 2028, subject to Priority Review and approval on the anticipated timeline. The FDA also cleared the IND for DYNE-302 in FSHD in July 2026, expanding the clinical pipeline.
Spending increased as the company moved its lead programs through manufacturing, clinical activity and commercial preparation. R&D expenses were $152.2 million for the three months ended June 30, 2026 compared to $99.2 million for the three months ended June 30, 2025, primarily due to increased manufacturing activity and higher clinical costs related to z-rostudirsen and z-basivarsen. G&A expenses were $29.5 million compared to $16.6 million, primarily due to costs in preparation for the potential z-rostudirsen launch. Net loss was $178.6 million, or $1.08 per basic and diluted share, compared with $110.9 million, or $0.97 per basic and diluted share.
Liquidity was reinforced after quarter end. Cash, cash equivalents and marketable securities were $898.5 million as of June 30, 2026. In July 2026, Dyne completed an underwritten public offering of 21,045,000 shares at $20.50 per share, producing approximately $431 million of gross proceeds and estimated net proceeds of approximately $405.0 million. The company also expanded its Hercules Capital term loan facility to up to $400 million and expects its June 30 cash resources together with the offering proceeds to fund operations into the second quarter of 2028.
The principal execution points are regulatory review of z-rostudirsen, ACHIEVE REC data and the potential z-basivarsen BLA path. The financial profile remains one of substantial development and launch investment, with no revenue, margin, operating cash flow or free cash flow reported in the supplied release. The supplied condensed statement of operations is labeled as being for the three months ended March 31, 2026 and 2025, while the narrative financial results identify the three months ended June 30, 2026 and 2025; the analysis relies on the narrative for the reported second-quarter figures.
Management, verbatim
We continue to make significant progress as we execute on our goal of delivering functional improvement for people living with genetically driven neuromuscular diseases.
John Cox, president and chief executive officer of Dyne
The FDA’s acceptance of our BLA for z-rostudirsen marks an important milestone for individuals living with DMD amenable to exon 51 skipping and a defining step in Dyne’s evolution toward becoming a commercial-stage company in the near future.
John Cox, president and chief executive officer of Dyne
Across our portfolio, we have achieved key clinical and regulatory milestones, including completion of enrollment in the registrational expansion cohort of ACHIEVE, initiation of the global confirmatory Phase 3 HARMONIA and FORZETTO trials, and FDA clearance of our IND for FSHD, underscoring the breadth of opportunity enabled by our FORCE™ platform.
John Cox, president and chief executive officer of Dyne
Not in the filing
stated, not guessed- Total revenue and any revenue comparison
- Revenue by segment
- Gross profit and gross margin
- Operating income or loss explicitly identified for the three months ended June 30, 2026
- Total operating expenses explicitly identified for the three months ended June 30, 2026
- Prior-quarter financial comparisons
- Operating cash flow
- Free cash flow
- Cash flow statement details
- Debt outstanding, interest expense and maturity details
- Share repurchases, dividends or other shareholder capital returns
- Financial revenue, gross margin, operating expense or tax-rate guidance
- Non-GAAP financial measures
- A complete balance sheet
- The condensed statement of operations in the supplied filing is labeled for the three months ended March 31, 2026 and 2025, which conflicts with the June 30, 2026 and 2025 periods stated in the narrative financial-results section.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Dyne is a clinical-stage neuromuscular biotech with lead programs z-rostudirsen (DMD exon 51) and z-basivarsen (DM1), using its FORCE platform.
Ticker impact
Dyne reports FDA acceptance of its z-rostudirsen BLA with Priority Review and a PDUFA target date of Jan 21, 2027.
Near-term upside bias as traders price the Jan 21, 2027 decision risk, with volatility around FDA communications and trial/filing follow-ups.
The filing is an SEC 8-K disclosure of a fresh FDA action (BLA accepted, Priority Review granted, PDUFA target set), which is a concrete catalyst rather than commentary. The company also reiterates cash runway into Q2 2028, reducing near-term financing overhang.
Market effects
Supports sentiment for exon-skipping DMD therapeutics and the broader neuromuscular rare-disease biotech space by reinforcing FDA willingness to move quickly on BLA filings.
Limited, primarily affects US-listed rare-disease biotech sentiment.
Moderate, as the company also references non-US approval pathways, but the concrete catalyst is US FDA review timing.
Counterpoint
Priority Review and BLA acceptance do not guarantee approval; traders may fade the move if they expect additional FDA questions or if manufacturing/CMC issues emerge before the PDUFA date.
Key entities
- companyDyne Therapeutics, Inc.
Nasdaq-listed clinical-stage neuromuscular biotech disclosing FDA BLA acceptance and Priority Review for z-rostudirsen, plus financing updates.
- drug_programz-rostudirsen (DYNE-251)
DMD exon 51 skipping candidate; BLA accepted for review with Priority Review and PDUFA target Jan 21, 2027.
- drug_programz-basivarsen (DYNE-101)
DM1 candidate; ACHIEVE registrational expansion enrollment completed, topline planned for Q1 2027.
- financing_counterpartyHercules Capital, Inc.
Counterparty to an amended non-dilutive senior secured term loan facility expanded to up to $400 million.
